It really shouldn't matter a lick what price a stock is trading at. There is no fundamental difference between a stock with 1 million shares trading at $50 and a stock with 10 million shares trading at $5.
Then again, there are people whose interest is piqued when they see a low price tag. It's one of the reasons why many companies will split their stock. The lower price tag will sometimes entice more buying.
When you consider the rule of large numbers, the phenomenon of lower-priced stocks rising faster than their higher-priced brethren does make a little sense. After all, for a stock trading at $5 to gain 50%, it has to only rise $2.50. But for a $100 stock, the same move takes $50.
Investors aren't always rational, and that $2.50 move seems a lot smaller than a $50 rise, even though they are the exact same in percentage terms.
Top Up And Coming Companies To Buy Right Now: ExamWorks Group Inc. (EXAM)
ExamWorks Group, Inc., together with its subsidiaries, provides independent medical examinations (IME), peer and bill reviews, and related services in the United States, Canada, the United Kingdom, and Australia. Its IME services are used by clients to confirm the veracity of claims by sick or injured individuals for workers� compensation, automotive, personal injury liability, and disability insurance coverage. The company also offers peer review services, including medical record reviews, nurse file reviews, and utilization reviews by members of its medical panel to provide medical opinion of a claimant�s condition and treatment; bill review services, such as physician and hospital bill reviews, and surgical cost estimates; and other IME related services comprising litigation support, medical record retrieval, administrative support services, and managed technology services. ExamWorks Group, Inc. provides its services through its medical panel of independently contract ed physicians and other medical providers. It serves property and casualty insurance carriers, law firms, third-party claim administrators, government agencies, and state funds. The company was incorporated in 2007 and is headquartered in Atlanta, Georgia.
Advisors' Opinion:- [By Roberto Pedone]
Examworks Group (EXAM) is a provider of independent medical examinations, peer and bill reviews and related services. This stock closed up 9.4% at $24.28 in Wednesday's trading session.
Wednesday's Volume: 1.62 million
Three-Month Average Volume: 209,788
Volume % Change: 583%From a technical perspective, EXAM exploded higher here right off some near-term support at $21.91 with heavy upside volume. This stock has been uptrending strong for the last six months, with shares soaring higher from its low of $13.79 to its intraday high of $24.40. During that uptrend, shares of EXAM have been consistently making higher lows and higher highs, which is bullish technical price action. This move also pushed shares of EXAM into breakout territory, since the stock took out its former 52-week high at $23.56.
Traders should now look for long-biased trades in EXAM as long as it's trending above $23 or $22.50 and then once it sustains a move or close above Wednesday's high of $24.40 with volume that hits near or above 209,788 shares. If we get that move soon, then EXAM will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $28 to $30.
Best Low Price Stocks To Invest In Right Now: ANI Pharmaceuticals Inc (ANIP)
ANI Pharmaceuticals, Inc., incorporated on April 11, 2001, is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173, 00 square feet, the Company manufactures oral solid dose products, as well as liquids and topicals, including narcotics. Its other products include The Food and Drug Administration (FDA) approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. In December 2013, the Company acquired 31 generic drug products from Teva Pharmaceuticals, which includes 20 solid-oral immediate release products, four extended release products and seven liquid products.
The Company performs contract manufacturing for other pharmaceutical companies. It has launched three products and has 11 products in development. The Company�� targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities.
Advisors' Opinion:- [By Lisa Levin]
ANI Pharmaceuticals (NASDAQ: ANIP) shares climbed 9.42% to $20.79. The volume of ANI Pharmaceuticals shares traded was 651% higher than normal. ANI Pharmaceuticals shares have jumped 121.45% over the past 52 weeks, while the S&P 500 index has surged 25.37% in the same period.
Best Low Price Stocks To Invest In Right Now: Regis Corporation(RGS)
Regis Corporation owns, operates, and franchises hairstyling and hair care salons in the United States, the United Kingdom, Canada, Puerto Rico, and internationally. It offers haircutting and styling, including shampooing and conditioning; hair coloring; and waving to men, women, and children. The company also owns and operates hair restoration centers, which provide hair systems, hair transplants, and hair therapy services, as well as hair care products. Its salons operate primarily under the Regis Salons, MasterCuts, SmartStyle, Supercuts, Cost Cutters, Sassoon, Promenade salons, Hair Masters, First Choice Haircutters, Magicuts, and Hair Club trade names in regional shopping malls, strip centers, lifestyle centers, Wal-Mart supercenters, department stores, mass merchants, and high-street locations. As of June 30, 2011, the company owned, franchised, or held ownership interests in approximately 12,700 locations. Regis Corporation was founded in 1922 and is headquartered i n Edina, Minnesota.
Advisors' Opinion:- [By Jake L'Ecuyer]
Regis (NYSE: RGS) shares tumbled 9.13 percent to $12.20 after the company reported downbeat Q2 results.
Idenix Pharmaceuticals (NASDAQ: IDIX) was down, falling 9.45 percent to $6.61 after JMP Securities downgraded the stock from Market Perform to Market Underperform.
- [By Amal Singh]
Some companies in the beauty and personal care segment have one important characteristic -- a recession-proof nature, which is a result of everyone's desire to look beautiful and young. This brings us to Ulta Salon, Cosmetics & Fragrance (NASDAQ: ULTA ) and Sally Beauty Holdings (NYSE: SBH ) . Both have performed quite well over the last few years, as shown in the chart below, even during the recession (the gray area being the recession period). Their performance stands in stark contrast to that of�Regis (NYSE: RGS ) , which has seen its top line drop continuously after peaking in 2008.
- [By Lauren Pollock]
Regis Corp.(RGS), the parent of haircut chains such as Supercuts, named Gap Inc.(GPS) (GPS) executive Jim Lain as chief operating officer, effective Nov. 11.
Best Low Price Stocks To Invest In Right Now: ATA Inc.(ATAI)
ATA Inc., through its subsidiaries, provides computer-based testing services in the People?s Republic of China. It offers services for the creation and delivery of computer-based tests utilizing its test delivery platform, proprietary testing technologies, and testing services; and provides logistical support services relating to test administration. The company?s computer-based testing services are used for professional licensure and certification tests in various industries, including information technology (IT) services, banking, securities, teaching, and insurance. Its e-testing platform integrates various aspects of the test delivery process for computer-based tests ranging from test form compilation to test scoring, and results analysis. ATA also provides career-oriented educational services, such as single course programs, degree major course programs, and pre-occupational training programs focusing on preparing students to pass IT and other vocational certification tests; test preparation and training programs and services to test candidates preparing to take professional certification tests in securities, futures, banking, insurance and teaching industries; online test preparation and training platform for the securities and banking industries; and test preparation software for the teaching industry. In addition, the company offers HR select employee assessment solution, an online system that utilizes its proprietary software and an inventory of test titles to help employers improve the efficiency and accuracy of their employee recruitment process. As of March 31, 2010, it had contractual relationships with 1,988 ATA authorized test centers. The company serves Chinese governmental agencies, professional associations, IT vendors, and Chinese educational institutions, as well as individual test preparation services. ATA Inc. was founded in 1999 and is based in Beijing, the People?s Republic of China.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Industrials stocks gained Friday, with ATA (NASDAQ: ATAI) leading advancers. Meanwhile, gainers in the sector included Plug Power (NASDAQ: PLUG), with shares up 22 percent, and Korn/Ferry International (KFY), with shares up 12 percent. In trading on Friday, basic materials shares were relative laggards, down on the day by about 1.36 percent.
Best Low Price Stocks To Invest In Right Now: Companhia de Bebidas das Americas - AmBev(ABV)
Companhia de Bebidas das Americas?Ambev engages in the production, distribution, and sale of beer, draft beer, carbonated soft drinks, malt, and other non-alcoholic and non-carbonated products in the Americas. It also sells bottled water, isotonics, and ready-to-drink teas. The company provides its products under the brand names of Skol, Brahma, Antarctica, Guarana Antarctica, Gatorade, Brahva, Brahva Beats, Extra, Brahma Light, Brahma Ice, Quilmes, Stella Artois, Red Rock, Pepsi-Cola, Seven UP, Zenda, Concordia, Triple Kola, Quilmes Cristal, Brahma, Andes, Pacena, Taquina, Huari, Becker, Baltica, Pilsen, Patricia, Labatt Blue, Alexander Keith?s, and Kokanee. It has a licensing agreement with Anheuser-Busch, Inc. to produce, bottle, distribute, and sell Budweiser products in Canada and Paraguay. Companhia de Bebidas das Americas?Ambev distributes its products through direct distribution system and third-party distributors. The company was founded in 1888 and is headquarter ed in Sao Paulo, Brazil. Companhia de Bebidas das Americas?Ambev is a subsidiary of Interbrew International B.V.
Advisors' Opinion:- [By Dividend]
Companhia de Bebidas Das Americas (ABV) has a market capitalization of $118.32 billion. The company employs 51,299 people, generates revenue of $14.120 billion and has a net income of $4.662 billion. Companhia de Bebidas Das Americas�� earnings before interest, taxes, depreciation and amortization (EBITDA) amounts to $6.829 billion. The EBITDA margin is 48.36 percent (the operating margin is 43.00 percent and the net profit margin 33.02 percent).
Best Low Price Stocks To Invest In Right Now: Micromem Technologies Inc (MMTIF)
Micromem Technologies Inc. (Micromem), incorporated on October 21, 1985, is a development-stage company. The Company is engaged in the development of memory technology that has the characteristics of non-volatility, which is the ability to retain information after power has been shut off. The Company is focused on magnetic sensor applications. The Company is focused on research and development of nano-magnetic random access memory (MRAM). Micromem operates in a single segment as a developer of non-volatile magnetic memory and sensor technology. The Company partners with industry to manufacture.
The Company�� technology is based on the ability to use magnetic materials in combination with a sensor to record the state of magnetization. Each magnetic element stores one bit of data based on its ability to alternate between states of magnetic polarization, which states are determined by a sensor.
The Company competes with IBM.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
Best Low Price Stocks To Invest In Right Now: Rexahn Pharmaceuticals Inc (RNN)
Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.
Archexin
Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.
Serdaxin
Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.
Zoraxel
Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.
The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.
Advisors' Opinion:- [By Roberto Pedone]
One under-$10 biopharmaceutical player that's just starting to move into breakout territory is Rexahn Pharmaceuticals (RNN), which is engaged in the development of novel treatments for cancer to patients. This stock has been on fire so far in 2013, with shares up sharply by 62%.
If you take a look at the chart for Rexahn Pharmaceuticals, you'll notice that this stock has been uptrending strong for the last month, with shares moving higher from its low of 36 cents per share to its intraday high of 53 cents per share. During that uptrend, shares of RNN have been making mostly higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of RNN into breakout territory above some near-term overhead resistance levels at 49 cents to 50 cents per share. It's worth noting that volume today is tracking in extremely strong with over 3 million shares traded, versus its three-month average action of 1.22 million shares.
Traders should now look for long-biased trades in RNN if it manages to break out above Thursday's intraday high of 53 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 1.22 million shares. If that breakout hits soon, then RNN will set up to re-test or possibly take out its next major overhead resistance levels at 64 cents to its 52-week high at 66 cents per share. Any high-volume move above 66 cents to 67 cents per share could then send RNN towards its next major overhead resistance levels at 81 cents per share.
Traders can look to buy RNN off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average at 47 cents per share. One can also buy RNN off strength once it clears 53 cents per share with volume and then simply use a stop that sits a comfortable percentage from your entry point.
No comments:
Post a Comment